Hematological changes were studied after oral administration of lindane (gamma-hexachlorocyclohexane) at 5 mg/kg body weight twice in 1 week in 6 species of agriculturally important birds: house sparrow, baya weaver bird, common myna, rose-ringed parakeet, blue rock pigeon and domestic duck. Lindane induced anemia in the birds as judged by reduced RBC count, hematocrit and hemoglobin content with corresponding changes in MCV, MCH and MCHC. Bleeding and clotting time were markedly prolonged. Splenic cell counts were decreased with marginal increase of splenic weight in most of the lindane fed birds. Total leucocyte counts were increased while the differential counts of WBC show marked heterophilia and eosinophilia with a decrease in monocyte, lymphocyte and basophil numbers. Domestic duck appears to be somewhat resistant compared to the wild birds studied. Besides anemia the results suggest both immunosuppression and stress effects and indicate that early hematological changes induced by lindane may serve as an initial warning for pesticide toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0300-483x(86)90050-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of menopause and age on breast density and background parenchymal enhancement in dynamic contrast-enhanced magnetic resonance imaging.
J Med Imaging (Bellingham)
November 2025
University of Toronto, Department of Medical Biophysics, Toronto, Ontario, Canada.
Purpose: Breast density (BD) and background parenchymal enhancement (BPE) are important imaging biomarkers for breast cancer (BC) risk. We aim to evaluate longitudinal changes in quantitative BD and BPE in high-risk women undergoing dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), focusing on the effects of age and transition into menopause.
Approach: A retrospective cohort study analyzed 834 high-risk women undergoing breast DCE-MRI for screening between 2005 and 2020.
Mitochondria-associated non-coding RNAs and their impact on drug resistance.
Front Pharmacol
February 2025
Department of Core Facility, The First Hospital of Jilin University, Changchun, Jilin, China.
Drug resistance is a prevalent challenge in clinical disease treatment, often leading to disease relapse and poor prognosis. Therefore, it is crucial to gain a deeper understanding of the molecular mechanisms underlying drug resistance and to develop targeted strategies for its effective prevention and management. Mitochondria, as vital energy-producing organelles within cells, have been recognized as key regulators of drug sensitivity.
View Article and Find Full Text PDFThe Novel Role of the Expression of Toll-like Receptors TLR-5, TLR-6, and TLR-9 and Associated Up-Regulation of Programmed Cell Death 1 Receptor (PD-1) and Its Ligand (PD-L1) in Lung Sepsis.
Int J Mol Sci
March 2025
First Department of Surgery, National and Kapodistrian University of Athens, "Laikon" General Hospital, 115 27 Athens, Greece.
Sepsis is a leading cause of death in hospitalized patients. The underlying pathophysiologic mechanisms of sepsis have not been fully elucidated thus far. The receptor of programmed cell death 1 (PD-1) and its ligand (PD-L1), in combination with the Toll-like receptors (TLRs), seem to contribute considerably in systematic responses during sepsis.
View Article and Find Full Text PDFUnusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas.
Int J Mol Sci
February 2025
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands.
Due to the minimal survival benefits of existing therapies for pediatric diffuse midline glioma (DMG) patients, new therapeutic modalities are being investigated. Immunotherapies such as CAR-T cells and oncolytic viruses (OVs) are part of these efforts, as evidenced by the increasing number of clinical trials. αβ T cells engineered with a high-affinity γ9δ2 T-cell receptor (TEGs) are immune cells designed to target metabolic changes in malignant or virally infected cells via BTN2A1 and BTN3A.
View Article and Find Full Text PDFNo Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the Transcript Level.
Int J Mol Sci
February 2025
Hematology Section, A.O.U. Policlinico "G. Martino", University of Messina, 98100 Messina, Italy.
Hydroxyurea (HU) cytoreduction is usually administered to patients with chronic myeloid leukemia before starting any tyrosine kinase inhibitors (TKIs) therapy. However, up to date, there is no evidence of any benefit of hydroxyurea pre-treatment. Conversely, evidence has been provided on both the prognostic significance of the quantitative assessment of expression at diagnosis and the individual decline of the slope.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!